Limitations of cholesterol lowering with PCSK9 inhibitors

Affiliations

Comment

Gilbert Thompson. Lancet Diabetes Endocrinol. 2017 Apr.

. 2017 Apr;5(4):241-243.

doi: 10.1016/S2213-8587(17)30060-8. Epub 2017 Feb 16.

¹ Metabolic Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK. Electronic address: g.thompson@imperial.ac.uk.

No abstract available

Comment on

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA. Raal FJ, et al. Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290. doi: 10.1016/S2213-8587(17)30044-X. Epub 2017 Feb 16. Lancet Diabetes Endocrinol. 2017. PMID: 28215937 Clinical Trial.